Company Filing History:
Years Active: 2023-2025
Title: Changyong Eun: Innovator in Pharmaceutical Formulations
Introduction
Changyong Eun is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of modified interleukin-7 fusion proteins. With a total of 2 patents, his work is paving the way for advancements in medical treatments.
Latest Patents
Changyong Eun's latest patent focuses on the formulation of a modified interleukin-7 fusion protein. This innovative pharmaceutical formulation comprises a modified IL-7 protein, a basal buffer with a concentration of 10 to 50 mM, a sugar with a concentration of 2.5 to 5 w/v %, and a surfactant with a concentration of 0.05 to 6 w/v %. Notably, this formulation does not show aggregates formation and demonstrates protective effects on proteins under stress conditions such as oxidation or agitation. As a result, it can be effectively used for the treatment of patients.
Career Highlights
Changyong Eun is currently associated with Genexine, Inc., where he continues to push the boundaries of pharmaceutical innovation. His expertise in protein formulations has been instrumental in the company's research and development efforts.
Collaborations
Throughout his career, Changyong Eun has collaborated with notable colleagues, including Donghoon Choi and Seong Hoon Jeong. These collaborations have further enhanced the impact of his work in the field.
Conclusion
Changyong Eun's contributions to pharmaceutical formulations, particularly in the area of modified interleukin-7 fusion proteins, highlight his role as an innovator in the medical field. His work not only advances scientific knowledge but also holds the potential for significant therapeutic applications.